For decades, patients who survived a heart attack were routinely told to stay on beta-blockers for life. But new research is challenging that long-standing approach, suggesting many stable patients may not need the medication indefinitely.
Beta-blockers, which lower heart rate and blood pressure, have been a cornerstone of post–heart attack care for more than 40 years. They were originally shown to reduce the risk of another cardiac event at a time when treatment options were more limited.
Now, experts say the science—and the standard of care—are evolving.
A major new study, known as the SMART-DECISION trial, found that stopping beta-blockers after one year was just as safe as continuing them in certain patients. The study followed more than 2,500 adults who were stable at least a year after a heart attack and had no heart failure or reduced heart function.
At about three years of follow-up, serious outcomes—including death, another heart attack or hospitalization for heart failure—occurred at similar rates in both groups.
“In stable low-risk patients… stopping beta-blockers was just as safe as continuing them,” said Dr. Joo-Yong Hahn, the study’s lead researcher.
That finding marks a significant shift from traditional guidance, which often recommended lifelong use regardless of a patient’s long-term stability.
Cardiologists say the change reflects broader advances in heart attack treatment. Today, patients benefit from faster interventions like angioplasty, as well as improved medications such as statins and blood thinners—reducing the need for older therapies to carry the full burden of protection.
“The evidence is changing,” said Dr. Manesh Patel of the American Heart Association. “For patients that are stable… you could potentially stop chronic beta-blocker therapy.”
Updated guidelines are already beginning to reflect that shift. In recent years, experts have moved away from recommending long-term beta-blockers for patients without a recent heart attack or ongoing heart dysfunction.
The new research goes a step further—suggesting that even after a heart attack, long-term use may not be necessary for everyone.
Doctors emphasize, however, that this does not apply to all patients. Beta-blockers remain essential for people with heart failure, reduced heart function or other conditions that require them.
Instead, the new approach centers on individualized care.
“This is not an essential medication in this population… and we are at liberty to peel it off, if it is appropriate,” said Dr. Nicole Bhave, a cardiologist at the University of Michigan.
For patients, the change could mean fewer medications, fewer side effects—such as fatigue or dizziness—and lower long-term costs.
Still, experts caution that any decision to stop beta-blockers should be made carefully, with a doctor’s guidance and ongoing monitoring.
The takeaway: lifelong treatment is no longer automatic. For many heart attack survivors, doctors are now asking whether beta-blockers are still needed after the first year.